AGE
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-31-2019 | 03-31-2019 | 03-31-2019 | |
|---|---|---|---|
| Actual EPS | -0.09 | -0.09 | -0.09 |
| Consensus EPS | |||
| Estimated EPS | |||
| Number of Estimates | |||
| EPS Surprise |
Stats
Summary
Sector:
Industry:
Short Interest ():
Ethical Flags
Longest drawdown: 130 trading days
From: 2018-12-03 To: 2019-06-12
Lowest Point:
AgeX Therapeutics reports Q1 results
via: SeekingAlpha at 2019-05-15 12:22:38:000
AgeX Therapeutics (NYSEMKT: AGE ): Q1 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics reports Q1 results
via: SeekingAlpha at 2019-05-15 12:22:38:000
AgeX Therapeutics (NYSEMKT: AGE ): Q1 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics reports Q1 results
via: SeekingAlpha at 2019-05-15 12:22:38:000
AgeX Therapeutics (NYSEMKT: AGE ): Q1 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
via: Business Wire at 2019-05-15 12:05:00:000
Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5 million from the exercise of warrants in March 2019 Presented at four industry and investor conferences AgeX Therapeutics , Inc. (&#… read more...
AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
via: Business Wire at 2019-05-15 12:05:00:000
Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5 million from the exercise of warrants in March 2019 Presented at four industry and investor conferences AgeX Therapeutics , Inc. (&#… read more...
AgeX Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update
via: Business Wire at 2019-05-15 12:05:00:000
Published data in peer-reviewed scientific journal to advance potential cell therapy AgeX-BAT1 for Type II Diabetes and obesity Received $4.5 million from the exercise of warrants in March 2019 Presented at four industry and investor conferences AgeX Therapeutics , Inc. (&#… read more...
AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
via: Business Wire at 2019-05-01 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity , an evening event from Aikora Health and Foresight Institute , on Wednesday, May 1, in San Francisco…. read more...
AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
via: Business Wire at 2019-05-01 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity , an evening event from Aikora Health and Foresight Institute , on Wednesday, May 1, in San Francisco…. read more...
AgeX Therapeutics to Participate at Biotech Investing in Longevity from Aikora Health and Foresight Institute
via: Business Wire at 2019-05-01 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, will participate at Biotech Investing in Longevity , an evening event from Aikora Health and Foresight Institute , on Wednesday, May 1, in San Francisco…. read more...
AgeX Therapeutics to Present at Master Investor Show 2019
via: Business Wire at 2019-04-05 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019 , in association with Fidelity International , on Saturday, April 6 in Londo… read more...
AgeX Therapeutics to Present at Master Investor Show 2019
via: Business Wire at 2019-04-05 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019 , in association with Fidelity International , on Saturday, April 6 in Londo… read more...
AgeX Therapeutics to Present at Master Investor Show 2019
via: Business Wire at 2019-04-05 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019 , in association with Fidelity International , on Saturday, April 6 in Londo… read more...
AgeX Therapeutics to Present at Master Investor Show 2019
via: Business Wire at 2019-04-05 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019 , in association with Fidelity International , on Saturday, April 6 in Londo… read more...
AgeX Therapeutics to Present at Master Investor Show 2019
via: Business Wire at 2019-04-05 04:00:00:000
AgeX Therapeutics , Inc. (AgeX; NYSE American: AGE), a biotechnology company focused on therapeutics for human aging, announced today that the company will participate at Master Investor Show 2019 , in association with Fidelity International , on Saturday, April 6 in Londo… read more...
AgeX Therapeutics reports Q4 results
via: SeekingAlpha at 2019-04-01 12:55:48:000
AgeX Therapeutics (NYSEMKT: AGE ): Q4 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics reports Q4 results
via: SeekingAlpha at 2019-04-01 12:55:48:000
AgeX Therapeutics (NYSEMKT: AGE ): Q4 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics reports Q4 results
via: SeekingAlpha at 2019-04-01 12:55:48:000
AgeX Therapeutics (NYSEMKT: AGE ): Q4 GAAP EPS of -$0.09. More news on: AgeX Therapeutics, Inc., Earnings news and commentary, , Read more … read more...
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
via: Business Wire at 2019-04-01 12:48:00:000
Ends 2018 with triad of innovative cell therapy technologies: UniverCyte for immune tolerance, PureStem for cell derivation and manufacturing, and HyStem for cell delivery Potential to generate any human cell type with clinical and commercial friendly characteri… read more...
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
via: Business Wire at 2019-04-01 12:48:00:000
Ends 2018 with triad of innovative cell therapy technologies: UniverCyte for immune tolerance, PureStem for cell derivation and manufacturing, and HyStem for cell delivery Potential to generate any human cell type with clinical and commercial friendly characteri… read more...
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update
via: Business Wire at 2019-04-01 12:48:00:000
Ends 2018 with triad of innovative cell therapy technologies: UniverCyte for immune tolerance, PureStem for cell derivation and manufacturing, and HyStem for cell delivery Potential to generate any human cell type with clinical and commercial friendly characteri… read more...
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
via: Business Wire at 2019-03-22 03:00:00:000
AgeX Therapeutics , Inc. (AgeX, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 … read more...
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
via: Business Wire at 2019-03-22 03:00:00:000
AgeX Therapeutics , Inc. (AgeX, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 … read more...
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
via: Business Wire at 2019-03-22 03:00:00:000
AgeX Therapeutics , Inc. (AgeX, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 … read more...
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
via: Business Wire at 2019-03-22 03:00:00:000
AgeX Therapeutics , Inc. (AgeX, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 … read more...
AgeX Therapeutics Receives $4.5 Million From Exercise of Warrants
via: Business Wire at 2019-03-22 03:00:00:000
AgeX Therapeutics , Inc. (AgeX, NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that it has received $4.5 million from the exercise of AgeX common stock warrants. Warrant holders purchased a total of 1,800,000 … read more...
AgeX Therapeutics to Present at Undoing Aging 2019, March 28-30 in Berlin, Germany
via: Business Wire at 2019-03-21 03:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on innovative therapeutics for human aging, announced today that the company will present in multiple sessions at Undoing Aging 2019 , March 28-30 in Berlin, Germany. Details of the companys particip… read more...
LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
via: Business Wire at 2019-03-07 02:00:00:000
LifeMap Sciences ( LifeMap ), a subsidiary of AgeX Therapeutics , Inc. (NYSE American: AGE), announced today that it has entered into a collaboration with iCarbonX Research Shenzhen , enabling iCarbonX to leverage LifeMaps GeneCards Suite platform in product… read more...
LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
via: Business Wire at 2019-03-07 02:00:00:000
LifeMap Sciences ( LifeMap ), a subsidiary of AgeX Therapeutics , Inc. (NYSE American: AGE), announced today that it has entered into a collaboration with iCarbonX Research Shenzhen , enabling iCarbonX to leverage LifeMaps GeneCards Suite platform in product… read more...
LifeMap Sciences and iCarbonX Research Shenzhen Announce Strategic Collaboration
via: Business Wire at 2019-03-07 02:00:00:000
LifeMap Sciences ( LifeMap ), a subsidiary of AgeX Therapeutics , Inc. (NYSE American: AGE), announced today that it has entered into a collaboration with iCarbonX Research Shenzhen , enabling iCarbonX to leverage LifeMaps GeneCards Suite platform in product… read more...
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
via: Business Wire at 2019-01-31 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that the company will present at Longevity Leaders , February 4 in London, United Kingdom. Details of the company&#x… read more...
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
via: Business Wire at 2019-01-31 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that the company will present at Longevity Leaders , February 4 in London, United Kingdom. Details of the company&#x… read more...
AgeX Therapeutics to Present at Longevity Leaders Conference, February 4 in London
via: Business Wire at 2019-01-31 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that the company will present at Longevity Leaders , February 4 in London, United Kingdom. Details of the company&#x… read more...
AgeX Therapeutics' CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
via: Business Wire at 2019-01-22 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019 , January 21 in Silico… read more...
AgeX Therapeutics' CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
via: Business Wire at 2019-01-22 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019 , January 21 in Silico… read more...
AgeX Therapeutics' CEO Dr. Michael D. West Presents at Precision Medicine World Conference 2019
via: Business Wire at 2019-01-22 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, announced today that Founder and CEO Michael D. West, Ph.D. presented at Precision Medicine World Conference 2019 , January 21 in Silico… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-01-10 12:46:27:000
Gainers: Inpixon (NASDAQ: INPX ) +42% . PLx Pharma (NASDAQ: PLXP ) +31% . Novan (NASDAQ: NOVN ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +22% . 500.com (NYSE: WBAI ) +25% . Fang Holdings (NYSE: SFUN ) +22% . Veritone (NASDAQ: VERI ) +19% . CooTek (NYSE: CTK ) +17% . SAExplora… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-01-10 12:46:27:000
Gainers: Inpixon (NASDAQ: INPX ) +42% . PLx Pharma (NASDAQ: PLXP ) +31% . Novan (NASDAQ: NOVN ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +22% . 500.com (NYSE: WBAI ) +25% . Fang Holdings (NYSE: SFUN ) +22% . Veritone (NASDAQ: VERI ) +19% . CooTek (NYSE: CTK ) +17% . SAExplora… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-01-10 12:46:27:000
Gainers: Inpixon (NASDAQ: INPX ) +42% . PLx Pharma (NASDAQ: PLXP ) +31% . Novan (NASDAQ: NOVN ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +22% . 500.com (NYSE: WBAI ) +25% . Fang Holdings (NYSE: SFUN ) +22% . Veritone (NASDAQ: VERI ) +19% . CooTek (NYSE: CTK ) +17% . SAExplora… read more...
LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
via: Business Wire at 2019-01-10 08:00:00:000
Novogene Tianjin to offer end-to-end sequencing through interpretation and reporting by integrating LifeMaps leading TGex Clinical NGS tertiary analysis platform with their sequencing and bioinformatics services in China Partnership to expand LifeMaps access to the C… read more...
LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
via: Business Wire at 2019-01-10 08:00:00:000
Novogene Tianjin to offer end-to-end sequencing through interpretation and reporting by integrating LifeMaps leading TGex Clinical NGS tertiary analysis platform with their sequencing and bioinformatics services in China Partnership to expand LifeMaps access to the C… read more...
LifeMap Sciences, Tianjin Novogene and Shanghai Shanyi Announce Strategic Partnership to Offer Leading Clinical NGS Solution to the China Market
via: Business Wire at 2019-01-10 08:00:00:000
Novogene Tianjin to offer end-to-end sequencing through interpretation and reporting by integrating LifeMaps leading TGex Clinical NGS tertiary analysis platform with their sequencing and bioinformatics services in China Partnership to expand LifeMaps access to the C… read more...
AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity
via: Business Wire at 2019-01-09 08:00:00:000
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as brown or … read more...
AgeX Therapeutics to Present at Biotech Showcase 2019
via: Business Wire at 2019-01-02 07:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase , to be held January 7-9, 2019 in San Francisco, California. AgeX Foun… read more...
AgeX Therapeutics to Present at Biotech Showcase 2019
via: Business Wire at 2019-01-02 07:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase , to be held January 7-9, 2019 in San Francisco, California. AgeX Foun… read more...
AgeX Therapeutics to Present at Biotech Showcase 2019
via: Business Wire at 2019-01-02 07:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase , to be held January 7-9, 2019 in San Francisco, California. AgeX Foun… read more...
Keeping Focused Amidst The Biotech Bear
via: SeekingAlpha at 2018-12-28 06:30:00:000
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...
Keeping Focused Amidst The Biotech Bear
via: SeekingAlpha at 2018-12-28 06:30:00:000
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...
Keeping Focused Amidst The Biotech Bear
via: SeekingAlpha at 2018-12-28 06:30:00:000
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...
Keeping Focused Amidst The Biotech Bear
via: SeekingAlpha at 2018-12-28 06:30:00:000
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...
Keeping Focused Amidst The Biotech Bear
via: SeekingAlpha at 2018-12-28 06:30:00:000
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2018-12-17 12:49:40:000
Gainers: Diffusion Pharmaceuticals (NASDAQ: DFFN ) +42% .NRC Group Holdings (NYSEMKT: NRCG ) +22% . Fidelity Southern (NASDAQ: LION ) +21% . HyreCar (NASDAQ: HYRE ) +18% . YRC Worldwide (NASDAQ: YRCW ) +19% . Axovant Sciences (NASDAQ: AXON ) +17% . AgeX Therapeutics (NYSE… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2018-12-17 12:49:40:000
Gainers: Diffusion Pharmaceuticals (NASDAQ: DFFN ) +42% .NRC Group Holdings (NYSEMKT: NRCG ) +22% . Fidelity Southern (NASDAQ: LION ) +21% . HyreCar (NASDAQ: HYRE ) +18% . YRC Worldwide (NASDAQ: YRCW ) +19% . Axovant Sciences (NASDAQ: AXON ) +17% . AgeX Therapeutics (NYSE… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2018-12-17 12:49:40:000
Gainers: Diffusion Pharmaceuticals (NASDAQ: DFFN ) +42% .NRC Group Holdings (NYSEMKT: NRCG ) +22% . Fidelity Southern (NASDAQ: LION ) +21% . HyreCar (NASDAQ: HYRE ) +18% . YRC Worldwide (NASDAQ: YRCW ) +19% . Axovant Sciences (NASDAQ: AXON ) +17% . AgeX Therapeutics (NYSE… read more...
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
via: Business Wire at 2018-11-29 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerati… read more...
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
via: Business Wire at 2018-11-29 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerati… read more...
AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference
via: Business Wire at 2018-11-29 08:00:00:000
AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerati… read more...
AgeX Therapeutics commence trading on NYSE
via: SeekingAlpha at 2018-11-29 07:28:42:000
AgeX Therapeutics'( AGE ) common stock is now trading on the NYSE American exchange under the symbol AGE. More news on: AgeX Therapeutics Inc, BioTime, Inc, Healthcare stocks news, Read more … read more...
AgeX Therapeutics commence trading on NYSE
via: SeekingAlpha at 2018-11-29 07:28:42:000
AgeX Therapeutics'( AGE ) common stock is now trading on the NYSE American exchange under the symbol AGE. More news on: AgeX Therapeutics Inc, BioTime, Inc, Healthcare stocks news, Read more … read more...
AgeX Therapeutics commence trading on NYSE
via: SeekingAlpha at 2018-11-29 07:28:42:000
AgeX Therapeutics'( AGE ) common stock is now trading on the NYSE American exchange under the symbol AGE. More news on: AgeX Therapeutics Inc, BioTime, Inc, Healthcare stocks news, Read more … read more...
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
via: Business Wire at 2018-11-29 07:00:00:000
Companys Common Stock Listed Under Symbol AGE AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is now trading on… read more...
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
via: Business Wire at 2018-11-29 07:00:00:000
Companys Common Stock Listed Under Symbol AGE AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is now trading on… read more...
AgeX Therapeutics, Inc. Shares Commence Trading on the NYSE American
via: Business Wire at 2018-11-29 07:00:00:000
Companys Common Stock Listed Under Symbol AGE AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced today that its common stock is now trading on… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|